Document Detail

Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction.
MedLine Citation:
PMID:  20176799     Owner:  NLM     Status:  MEDLINE    
AIMS: To assess the prognostic value of anti-apolipoprotein A-1 (anti-apoA-1) IgG after myocardial infarction (MI) and its association with major cardiovascular events (MACEs) at 12 months and to determine their association with resting heart rate (RHR), a well-established prognostic feature after MI. Anti-apoA-1 IgG have been reported in MI without autoimmune disease, but their clinical significance remains undetermined. METHODS AND RESULTS: A total of 221 consecutive patients with MI were prospectively included, and all completed a 12-month follow-up. Major cardiovascular events consisted in death, MI, stroke, or hospitalization either for an acute coronary syndrome or heart failure. Resting heart rate was obtained on Holter the day before discharge under the same medical treatment. Neonate rat ventricular cardiomyocytes (NRVC) were used in vitro to assess the direct anti-apoA-1 IgG effect on RHR. During follow-up, 13% of patients presented a MACE. Anti-apoA-1 IgG positivity was 9% and was associated with a higher RHR (P = 0.0005) and higher MACE rate (adjusted OR, 4.3; 95% CI, 1.46-12.6; P = 0.007). Survival models confirmed the significant nature of this association. Patients with MACE had higher median anti-apoA-1 IgG values at admission than patients without (P = 0.007). On NRVC, plasma from MI patients and monoclonal anti-apoA-1 IgG induced an aldosterone and dose-dependent positive chronotropic effect, abrogated by apoA-1 and therapeutic immunoglobulin (IVIG) pre-incubation. CONCLUSIONS: In MI patients, anti-apoA-1 IgG is independently associated with MACE at 1-year, interfering with a currently unknown aldosterone-dependent RHR determinant. Knowing whether anti-apoA-1 IgG assessment could be of interest to identify an MI patient subset susceptible to benefit from apoA-1/IVIG therapy remains to be demonstrated.
Nicolas Vuilleumier; Michel F Rossier; Sabrina Pagano; Magaly Python; Emmanuel Charbonney; René Nkoulou; Richard James; Guido Reber; François Mach; Pascale Roux-Lombard
Related Documents :
22172429 - Rationale and design of the coronary artery bypass grafting surgery off or on pump reva...
8921479 - An assessment of the validity of icd code 410 to identify hospital admissions for myoca...
19641679 - Reduction in oxidative stress and modulation of heart failure subsequent to myocardial ...
1846569 - Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfus...
1892059 - Thrombolysis in postinfarction angina.
10728389 - Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium followi...
11804979 - Timi myocardial perfusion grade and st segment resolution: association with infarct siz...
14636759 - Roles of ischemia and hypoxia and the molecular pathogenesis of post-burn cardiac shock.
20430269 - Multicenter trial of high-speed versus conventional single-photon emission computed tom...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-22
Journal Detail:
Title:  European heart journal     Volume:  31     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-02     Completed Date:  2010-09-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  815-23     Citation Subset:  IM    
Service of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva 14, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / mortality
Aged, 80 and over
Apolipoprotein A-I / immunology*
Arrhythmias, Cardiac / diagnosis*,  physiopathology
Biological Markers / metabolism
Dose-Response Relationship, Immunologic
Enzyme-Linked Immunosorbent Assay
Heart Failure / mortality
Heart Rate / immunology
Immunoglobulin G / metabolism*
Middle Aged
Myocardial Infarction / diagnosis*,  mortality,  physiopathology
Myocytes, Cardiac / immunology
Prospective Studies
Rats, Wistar
Reference Values
Reproducibility of Results
Stroke / mortality
Treatment Outcome
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Biological Markers; 0/Immunoglobulin G

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for r...
Next Document:  Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global i...